# Programmable Microvesicles for Intracellular Macromolecule Delivery

> **NIH NIH R01** · UNIVERSITY OF COLORADO · 2024 · $101,056

## Abstract

Project Summary
Our project aims to develop a novel technology platform for delivering macromolecules intracellularly
overcoming the challenge of endosomal barriers. Justification for the AKTA Pure 25 M chromatography
system stems from the growing demand for isolating and purifying biological nanoparticles, like
gectosomes, crucial for therapeutic development. Existing methods lack scalability and reproducibility.
The AKTA Pure 25 M's automation, scalability, and compatibility with high-resolution SEC columns are
essential for our research. It will enhance purification efficiency, improving gectosome quality and
scalability, accelerating our research timeline. In summary, the acquisition of the AKTA Pure 25 M will
provide a significant boost to our experimental studies, enhance research efficiency, and foster
collaboration within our research community. This investment will catalyze advancements in
intracellular biologic delivery, benefiting both basic research and therapeutic development endeavors.

## Key facts

- **NIH application ID:** 11035040
- **Project number:** 3R01GM144749-03S2
- **Recipient organization:** UNIVERSITY OF COLORADO
- **Principal Investigator:** XUEDONG LIU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $101,056
- **Award type:** 3
- **Project period:** 2022-02-01 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11035040

## Citation

> US National Institutes of Health, RePORTER application 11035040, Programmable Microvesicles for Intracellular Macromolecule Delivery (3R01GM144749-03S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11035040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*